Pharmaceutical Technology on MSN10h
Coave Therapeutics raises $33m in funding to advance ALIGATER platformCoave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.
Hosted on MSN1d
This is the reason you should train your back and biceps together—here’s how to do itBut when I do target specific body areas, I like to train muscle groups that typically work together—like the back and biceps ...
Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...
Abu Dhabi, United Arab Emirates;December 2024: In a groundbreaking operation that showcases M42's Danat Al Emarat Hospital ...
Growing concerns suggest Gen Z might be aging faster biologically due to elevated cortisol levels. Factors such as academic ...
PHILADELPHIA— Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can all differ ...
Heuser, J. E. & Reese, T. S.. Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction . J. Cell Biol. 133, 315– 344 (1973).
Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can ...
Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental ...
AliveGen USA Inc. (AliveGen), a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback